Patents by Inventor Timothy G. Dixon

Timothy G. Dixon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210393681
    Abstract: Disclosed are means, methods, and compositions of matter for prophylaxis and/or treatment of SARS-CoV-2 by administration of dendritic cells in a manner and frequency sufficient to induce activation of innate and/or adaptive immune responses. In one embodiment the invention teaches administration of dendritic cells pulsed with one or more innate immune stimulants in a manner endowing said dendritic cell with ability to induce augmentation of natural killer (NK) cell number and/or activity. In another embodiment the invention teaches the use of dendritic cells stimulated with innate immune activators in a manner to allow for uptake of viral particles and presentation of viral epitopes to T cells in order to stimulate immunological activation and/or memory responses.
    Type: Application
    Filed: June 22, 2020
    Publication date: December 23, 2021
    Applicant: Therapeutic Solutions International, Inc.
    Inventors: Thomas E. Ichim, Timothy G. Dixon, James Veltmeyer
  • Publication number: 20210386815
    Abstract: Disclosed are compositions of matter, treatments and protocols useful for reduction of number and/or activity of myeloid suppressor cells (MSC). In some embodiments the invention teaches the administration of a therapeutic combination of ingredients comprising of pterostilbene, Nigella sativa, sulforaphane, and epigallocatechin-3-gallate (EGCG) to a mammal at possessing an increased number and/or activity of said MSC in which reduction of number and/or activity is desired. In another embodiment, the invention teaches administration of said therapeutic combination to a mammal infected with viral and/or bacterial infections and/or neoplasia. In some embodiments dosage of said therapeutic combination is based on inflammatory and/or immunological parameters observed in patients.
    Type: Application
    Filed: June 11, 2020
    Publication date: December 16, 2021
    Applicant: Therapeutic Solutions International, Inc.
    Inventors: Thomas E. Ichim, Timothy G. Dixon, James Veltmeyer
  • Publication number: 20210338763
    Abstract: Disclosed herein are methods of treating or preventing complications associated with a SARS-CoV-2 infection, comprising: administration of a combination comprising: a) Green Tea and/or extract thereof; b) Blueberry and/or extract thereof; c) Nigella sativa and/or extract thereof; and d) broccoli and/or extract thereof in an amount and frequency sufficient to treat or prevent complications associated with said SARS-CoV-2 infection.
    Type: Application
    Filed: May 4, 2020
    Publication date: November 4, 2021
    Applicant: Therapeutic Solutions International, Inc.
    Inventors: Thomas E. Ichim, Timothy G. Dixon
  • Publication number: 20210128638
    Abstract: Disclosed are methods, means, and protocols for stimulation of rejuvenation in single cells, organs, and organisms by administration of cord blood derived plasma, cord blood plasma concentrates, and cord blood derived exosomes together with pterostilbene. The invention describes the previously unexpected finding that addition of pterostilbene to cord blood enhances the rejuvenation properties of cord blood. Said rejuvenation properties include telomere preservation, reduction in beta galactosidase, and retention of cellular activities.
    Type: Application
    Filed: November 4, 2020
    Publication date: May 6, 2021
    Applicant: Therapeutic Solutions International, Inc.
    Inventors: Thomas E. Ichim, Timothy G. Dixon
  • Patent number: 9682047
    Abstract: Compositions and methods useful to enhancing, improving, or eliciting anti-tumor immune responses are disclosed. A pterostilbene containing composition is administered to a cancer patient at a sufficient concentration and frequency to induce de-repression of tumor targeting immune responses. The composition enhances antibody dependent cellular toxicity (ADCC) and augments efficacy of antigen specific immunotherapeutics such as trastuzumab and other monoclonal antibody therapies useful for treating cancer.
    Type: Grant
    Filed: July 7, 2016
    Date of Patent: June 20, 2017
    Assignee: Therapeutic Solutions International, Inc.
    Inventors: Timothy G. Dixon, Gerry B. Berg, Robert F. Graham, Santosh Kesari, Thomas Ichim
  • Publication number: 20170020930
    Abstract: Methods for the treatment of pregnancy complications through immune modulation are disclosed. Also disclosed are probiotic compositions capable of inducing an anti-inflammatory immune response in a subject. The probiotic composition may include one or more of Streptococcus thermophiles, Lactobacillus reuteri, Bifidobacterium bifidium, Lactobacillus acidophilus, and Lactobacillus casei.
    Type: Application
    Filed: July 20, 2016
    Publication date: January 26, 2017
    Inventors: Thomas Ichim, Timothy G. Dixon
  • Publication number: 20160324801
    Abstract: Compositions and methods useful to enhancing, improving, or eliciting anti-tumor immune responses are disclosed. A pterostilbene containing composition is administered to a cancer patient at a sufficient concentration and frequency to induce de-repression of tumor targeting immune responses. The composition enhances antibody dependent cellular toxicity (ADCC) and augments efficacy of antigen specific immunotherapeutics such as trastuzumab and other monoclonal antibody therapies useful for treating cancer.
    Type: Application
    Filed: July 7, 2016
    Publication date: November 10, 2016
    Inventors: Timothy G. Dixon, Gerry B. Berg, Robert F. Graham, Santosh Kesari, Thomas Ichim